Immunotherapy in the Decade Ahead

2017 Kyoto Prize Symposium & BIOCOM

03/13/2017 03:30 p.m. - 06:15 p.m.

Life Sciences, Venture Intellectual Property, and Patent Counseling + Prosecution

Ida & Cecil Green Faculty Club
9500 Gilman Dr.
La Jolla, CA 92093

James J. Mullen III

James J. Mullen III

Sponsorship

Chrystel Gelin
cgelin@mofo.com
(858) 314-5475

Hundreds of clinical trials involving immunotherapy, alone or combined with other treatments, are underway for nearly every type of cancer.

Please join us for the rare opportunity to salute Kyoto Prize laureate Tasuku Honjo with a panel of seasoned leaders in the Life Sciences industry, discussing immunology, therapeutic, medical, and legal issues and the challenges in moving to market.

The panel is moderated by Biocom’s president and CEO Joe Panetta. Biocom is California’s largest and most-experienced leader and advocate for the Life Sciences industry working on behalf of more than 800 members with offices located in San Diego, Los Angeles, Tokyo, and Washington, D.C. The featured panelists are:

  • Tasuku Honjo, M.D., Ph.D. – 2016 Kyoto Prize Laureate – recognized for his discovery of the mechanism responsible for the functional diversification of antibodies, immunoregulatory molecules, and clinical applications of PD-1.
  • Hank Nordhoff, Chairman and CEO of Banyan Biomarkers, Inc., and Chair of Chugai Pharmaceuticals North America. CEO of Gen-probe for 15 years, Hank is also chair and board member of several of the most important research, engineering, medical and business non-profit organizations.
  • James J. Mullen III, Ph.D., J.D., Partner, Morrison & Foerster LLP, founder and head of the firm’s Antibody Patent Group and leader of the San Diego office Patent Group. Combining his scientific experience with his legal training, James crafts commercially relevant solutions for his clients’ intellectual property challenges.
  • Amy Mills, Ph.D., J.D., Vice President, Intellectual Property, Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize cancer treatment. Amy has over ten years’ experience in biotechnology and pharmaceutical patent law, with particular emphasis on helping clients in the biologics and immunotherapy spaces.

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2017 Morrison & Foerster LLP. All rights reserved.